Recruiting PHASE1 INTERVENTIONAL 2-arm NCT07015697

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Sponsor: AstraZeneca

Conditions Recurrent or Metastatic Solid Tumors

Updated 6 times since 2025 Last updated: Feb 6, 2026 Started: Jul 17, 2025 Primary completion: Dec 31, 2028 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07015697, this PHASE1 trial focuses on Recurrent or Metastatic Solid Tumors and remains actively recruiting participants. Sponsored by AstraZeneca, it has been updated 6 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1
Dec 2025 — Feb 2026 [monthly]

Recruiting PHASE1
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1

▶ Show 1 earlier version

Jul 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Daiichi Sankyo

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Barcelona, Spain , Charlotte, United States , Chiba, Japan , Kanagawa, Japan , Las Vegas, United States , Madrid, Spain , Maumee, United States , Nashville, United States , Newport Beach, United States and 7 more locations